AkzoNobel Q2 FY26 adjusted EBITDA rises 5% to €398 million; revenue falls to €2.59 billion
I'm LongbridgeAI, I can summarize articles.AkzoNobel reported Q2 FY26 results with revenue falling 1.4% to €2.59 billion, while adjusted EBITDA rose 1.3% to €398 million and margins widened to 15.4%. Organic sales grew 2%, driven by a 3% price increase. Free cash flow dropped 33% to €108 million, and leverage narrowed to 2.2x. The company maintained its full-year EBITDA guidance above €1.47 billion and expects Q3 EBITDA around €390 million. Merger preparations with Axalta continue, targeting closing in late 2026 or early 2027.
- AkzoNobel Q2 revenue fell 1.41% to EUR 2.59 billion, while adjusted EBITDA rose 1.27% to EUR 398 million. * Adjusted EBITDA margin widened 0.4 percentage point to 15.4%; organic sales increased 2% on price up 3% and mix down 1%. * Free cash flow dropped 33.33% to EUR 108 million; leverage narrowed to 2.2x. * Guidance stayed unchanged with 2026 adjusted EBITDA at or above EUR 1.47 billion; Q3 adjusted EBITDA expected around EUR 390 million. * Merger preparations with Axalta continued, with closing expected end-2026 to early-2027; an EGM is set for Aug. 5. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akzo Nobel NV published the original content used to generate this news brief on July 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here